Testosterone, estradiol and aromatase inhibitor therapy in elderly men

Journal of Steroid Biochemistry and Molecular Biology

Volumn 106, Issue 1-5, 2007, Pages 162-167

  Leder, Benjamin Z ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Aromatase therapy in elderly men

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; ANDROGEN; AROMATASE; AROMATASE INHIBITOR; C REACTIVE PROTEIN; CHOLESTEROL; DEOXYPYRIDINOLINE; ESTRADIOL; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; OSTEOCALCIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIACYLGLYCEROL;

AGING; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITION; ELDERLY CARE; ESTRADIOL BLOOD LEVEL; HUMAN; HYPOGONADISM; MALE; METABOLISM; PROSTATE DISEASE; SKELETON; TESTOSTERONE BLOOD LEVEL;

AGED; ANIMALS; AROMATASE INHIBITORS; BONE AND BONES; CARDIOVASCULAR DISEASES; COGNITION; ESTRADIOL; HUMANS; MALE; PROSTATIC DISEASES; RISK FACTORS; TESTOSTERONE;

EID: 34548493721     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.05.018     Document Type: Article

References (94)

1. Kaufman J.M., and Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 26 6 (2005) 833-876
2. Harman S.M., Metter E.J., Tobin J.D., Pearson J., and Blackman M.R. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J. Clin. Endocrinol. Metab. 86 2 (2001) 724-731
3. Ferrini R.L., and Barrett-Connor E. Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am. J. Epidemiol. 147 8 (1998) 750-754
4. Denti L., Pasolini G., Sanfelici L., Benedetti R., Cecchetti A., Ceda G.P., Ablondi F., and Valenti G. Aging-related decline of gonadal function in healthy men: correlation with body composition and lipoproteins. J. Am. Geriatr. Soc. 48 1 (2000) 51-58
5. van den Beld A.W., de Jong F.H., Grobbee D.E., Pols H.A., and Lamberts S.W. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J. Clin. Endocrinol. Metab. 85 9 (2000) 3276-3282
6. Vermeulen A., Kaufman J.M., Goemaere S., and van Pottelberg I. Estradiol in elderly men. Aging Male 5 2 (2002) 98-102
7. Burris A.S., Banks S.M., Carter C.S., Davidson J.M., and Sherins R.J. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J. Androl. 13 4 (1992) 297-304
8. Alexander G.M., Swerdloff R.S., Wang C., Davidson T., McDonald V., Steiner B., and Hines M. Androgen-behavior correlations in hypogonadal men and eugonadal men. II. Cognitive abilities. Horm. Behav. 33 2 (1998) 85-94
9. Christiansen K. Behavioural correlates of testosterone. In: Nieschlag S. (Ed). Testosterone: Action, Deficiency, Substitution. 2nd ed. (1998), Springer, Berlin
10. Bhasin S., Bross R., and Storer T. Androgens and muscles. In: Nieschlag S. (Ed). Testosterone: Action, Deficiency, Substitution,. 2nd ed. (1998), Springer, Berlin
11. Finkelstein J.S. Androgens and bone metabolism. In: Nieschlag S. (Ed). Testosterone: Action, Deficiency, Substitution. 2nd ed. (1998), Springer, Berlin
12. Jackson J.A., Riggs M.W., and Spiekerman A.M. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am. J. Med. Sci. 304 1 (1992) 4-8
13. Morley J.E., Perry H.M.D., Kaiser F.E., Kraenzle D., Jensen J., Houston K., Mattammal M., and Perry Jr. H.M. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J. Am. Geriatr. Soc. 41 2 (1993) 149-152
14. Sih R., Morley J.E., Kaiser F.E., Perry III H.M., Patrick P., and Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial [see comments]. J. Clin. Endocrinol. Metab. 82 6 (1997) 1661-1667
15. Tenover J.S. Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab. 75 4 (1992) 1092-1098
16. Hajjar R.R., Kaiser F.E., and Morley J.E. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J. Clin. Endocrinol. Metab. 82 11 (1997) 3793-3796
17. Snyder P.J., Peachey H., Hannoush P., Berlin J.A., Loh L., Lenrow D.A., Holmes J.H., Dlewati A., Santanna J., Rosen C.J., and Strom B.L. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. Metab. 84 8 (1999) 2647-2653
18. Snyder P.J., Peachey H., Hannoush P., Berlin J.A., Loh L., Holmes J.H., Dlewati A., Staley J., Santanna J., Kapoor S.C., Attie M.F., Haddad Jr. J.G., and Strom B.L. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. 84 6 (1999) 1966-1972
19. Veldhuis J.D., and Dufau M.L. Estradiol modulates the pulsatile secretion of biologically active luteinizing hormone in man. J. Clin. Invest. 80 3 (1987) 631-638
20. Finkelstein J.S., O'Dea L.S., Whitcomb R.W., and Crowley Jr. W.F. Sex steroid control of gonadotropin secretion in the human male. II. Effects of estradiol administration in normal and gonadotropin-releasing hormone-deficient men. J. Clin. Endocrinol. Metab. 73 3 (1991) 621-628
21. Schnorr J.A., Bray M.J., and Veldhuis J.D. Aromatization mediates testosterone's short-term feedback restraint of 24-hour endogenously driven and acute exogenous gonadotropin-releasing hormone-stimulated luteinizing hormone and follicle-stimulating hormone secretion in young men. J. Clin. Endocrinol. Metab 86 6 (2001) 2600-2606
22. Hayes F.J., Seminara S.B., Decruz S., Boepple P.A., and Crowley Jr. W.F. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback [see comments]. J. Clin. Endocrinol. Metab. 85 9 (2000) 3027-3035
23. Oursler M.J., Osdoby P., Pyfferoen J., Riggs B.L., and Spelsberg T.C. Avian osteoclasts as estrogen target cells. Proc. Natl. Acad. Sci. U.S.A. 88 15 (1991) 6613-6617
24. Eriksen E.F., Colvard D.S., Berg N.J., Graham M.L., Mann K.G., Spelsberg T.C., and Riggs B.L. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241 4861 (1988) 84-86
25. Colvard D.S., Eriksen E.F., Keeting P.E., Wilson E.M., Lubahn D.B., French F.S., Riggs B.L., and Spelsberg T.C. Identification of androgen receptors in normal human osteoblast-like cells. Proc. Natl. Acad. Sci. U.S.A. 86 3 (1989) 854-857
26. Kawano H., Sato T., Yamada T., Matsumoto T., Sekine K., Watanabe T., Nakamura T., Fukuda T., Yoshimura K., Yoshizawa T., Aihara K., Yamamoto Y., Nakamichi Y., Metzger D., Chambon P., Nakamura K., Kawaguchi H., and Kato S. Suppressive function of androgen receptor in bone resorption. Proc. Natl. Acad. Sci. U.S.A. 100 16 (2003) 9416-9421
27. Moverare S., Venken K., Eriksson A.L., Andersson N., Skrtic S., Wergedal J., Mohan S., Salmon P., Bouillon R., Gustafsson J.A., Vanderschueren D., and Ohlsson C. Differential effects on bone of estrogen receptor alpha and androgen receptor activation in orchidectomized adult male mice. Proc. Natl. Acad. Sci. U.S.A. 100 23 (2003) 13573-13578
28. Lindberg M.K., Moverare S., Skrtic S., Alatalo S., Halleen J., Mohan S., Gustafsson J.A., and Ohlsson C. Two different pathways for the maintenance of trabecular bone in adult male mice. J. Bone Miner. Res. 17 4 (2002) 555-562
29. Vidal O., Lindberg M.K., Hollberg K., Baylink D.J., Andersson G., Lubahn D.B., Mohan S., Gustafsson J.A., and Ohlsson C. Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice. Proc. Natl. Acad. Sci. U.S.A. 97 10 (2000) 5474-5479
30. Miyaura C., Toda K., Inada M., Ohshiba T., Matsumoto C., Okada T., Ito M., Shizuta Y., and Ito A. Sex- and age-related response to aromatase deficiency in bone. Biochem. Biophys. Res. Commun. 280 4 (2001) 1062-1068
31. Oz O.K., Zerwekh J.E., Fisher C., Graves K., Nanu L., Millsaps R., and Simpson E.R. Bone has a sexually dimorphic response to aromatase deficiency. J. Bone Miner. Res. 15 3 (2000) 507-514
32. Morishima A., Grumbach M.M., Simpson E.R., Fisher C., and Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J. Clin. Endocrinol. Metab. 80 12 (1995) 3689-3698
33. Smith E.P., Boyd J., Frank G.R., Takahashi H., Cohen R.M., Specker B., Williams T., Lubahn D.B., and Korach K.S. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331 16 (1994) 1056-1061
34. Bilezikian J.P., Morishima A., Bell J., and Grumbach M.M. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N. Engl. J. Med. 339 (1998) 599-603
35. Khosla S., Melton L.J., and Riggs B.L. Clinical review 144: estrogen and the male skeleton. J. Clin. Endocrinol. Metab. 87 (2002) 1443-1450
36. Leder B.Z., LeBlanc K.M., Schoenfeld D.A., Eastell R., and Finkelstein J.S. Differential effects of androgens and estrogens on bone turnover in normal men. J. Clin. Endocrinol. Metab. 88 (2003) 204-210
37. Taxel P., Kennedy D.G., Fall P.M., Willard A.K., Clive J.M., and Raisz L.G. The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. J. Clin. Endocrinol. Metab. 86 (2001) 2869-2874
38. Bates K.A., Harvey A.R., Carruthers M., and Martins R.N. Androgens, andropause and neurodegeneration: exploring the link between steroidogenesis, androgens and Alzheimer's disease. Cell Mol. Life Sci. 62 (2005) 281-292
39. Cappa S.F., Guariglia C., Papagno C., Pizzamiglio L., Vallar G., Zoccolotti P., Ambrosi B., and Santiemma V. Patterns of lateralization and performance levels for verbal and spatial tasks in congenital androgen deficiency. Behav. Brain Res. 31 (1988) 177-183
40. Gouchie C., and Kimura D. The relationship between testosterone levels and cognitive ability patterns. Psychoneuroendocrinology 16 (1991) 323-334
41. Christiansen K., and Knussmann R. Sex hormones and cognitive functioning in men. Neuropsychobiology 18 1 (1987) 27-36
42. Barrett-Connor E., Goodman-Gruen D., and Patay B. Endogenous sex hormones and cognitive function in older men. J. Clin. Endocrinol. Metab. 84 10 (1999) 3681-3685
43. Kenny A.M., Bellantonio S., Gruman C.A., Acosta R.D., and Prestwood K.M. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. J. Gerontol. A: Biol. Sci. Med. Sci. 57 5 (2002) M321-M325
44. Janowsky J.S., Chavez B., and Orwoll E. Sex steroids modify working memory. J. Cogn. Neurosci. 12 3 (2000) 407-414
45. Janowsky J.S., Oviatt S.K., and Orwoll E.S. Testosterone influences spatial cognition in older men. Behav. Neurosci. 108 2 (1994) 325-332
46. Cherrier M.M., Asthana S., Plymate S., Baker L., Matsumoto A.M., Peskind E., Raskind M.A., Brodkin K., Bremner W., Petrova A., LaTendresse S., and Craft S. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 57 1 (2001) 80-88
47. Rapp S.R., Espeland M.A., Shumaker S.A., Henderson V.W., Brunner R.L., Manson J.E., Gass M.L., Stefanick M.L., Lane D.S., Hays J., Johnson J., Coker L.H., Dailey M., and Bowen D. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the women's health initiative memory study: a randomized controlled trial. JAMA 289 20 (2003) 2663-2672
48. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., Hendrix S.L., Jones III B.N., Assaf A.R., Jackson R.D., Kotchen J.M., Wassertheil-Smoller S., and Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the women's health initiative memory study: a randomized controlled trial. JAMA 289 20 (2003) 2651-2662
49. Negri-Cesi P., Colciago A., Poletti A., and Motta M. 5alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3. Prostate 41 4 (1999) 224-232
50. Stanbrough M., Leav I., Kwan P.W., Bubley G.J., and Balk S.P. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc. Natl. Acad. Sci. U.S.A. 98 19 (2001) 10823-10828
51. Hsing A.W., and Comstock G.W. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2 1 (1993) 27-32
52. Nomura A., Heilbrun L.K., Stemmermann G.N., and Judd H.L. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res. 48 12 (1988) 3515-3517
53. Vatten L.J., Ursin G., Ross R.K., Stanczyk F.Z., Lobo R.A., Harvei S., and Jellum E. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol. Biomarkers Prev. 6 11 (1997) 967-969
54. Cunha G.R., Hayward S.W., Wang Y.Z., and Ricke W. Role of the stromal microenvironment in carcinogenesis of the prostate. Int. J. Cancer 107 1 (2003) 1-10
55. Risbridger G.P., Bianco J.J., Ellem S.J., and McPherson S.J. Oestrogens and prostate cancer. Endocr. Relat. Cancer 10 2 (2003) 187-191
56. Neubauer B.L., McNulty A.M., Chedid M., Chen K., Goode R.L., Johnson M.A., Jones C.D., Krishnan V., Lynch R., Osborne H.E., and Graff J.R. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model. Cancer Res. 63 18 (2003) 6056-6062
57. Jeyaraj D.A., Udayakumar T.S., Rajalakshmi M., Pal P.C., and Sharma R.S. Effects of long-term administration of androgens and estrogen on rhesus monkey prostate: possible induction of benign prostatic hyperplasia. J. Androl. 21 6 (2000) 833-841
58. Habenicht U.F., Schwarz K., Neumann F., and Etreby M.F. Induction of estrogen-related hyperplastic changes in the prostate of the cynomolgus monkey (Macaca fascicularis) by androstenedione and its antagonization by the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione. Prostate 11 4 (1987) 313-326
59. Suzuki K., Nakazato H., Matsui H., Koike H., Okugi H., Kashiwagi B., Nishii M., Ohtake N., Nakata S., Ito K., and Yamanaka H. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer 98 7 (2003) 1411-1416
60. Cancel-Tassin G., Latil A., Rousseau F., Mangin P., Bottius E., Escary J.L., Berthon P., and Cussenot O. Association study of polymorphisms in the human estrogen receptor alpha gene and prostate cancer risk. Eur. Urol. 44 4 (2003) 487-490
61. Tanaka Y., Sasaki M., Kaneuchi M., Shiina H., Igawa M., and Dahiya R. Polymorphisms of estrogen receptor alpha in prostate cancer. Mol. Carcinog. 37 4 (2003) 202-208
62. Freedman D.S., O'Brien T.R., Flanders W.D., DeStefano F., and Barboriak J.J. Relation of serum testosterone levels to high density lipoprotein cholesterol and other characteristics in men. Arterioscler. Thromb. 11 2 (1991) 307-315
63. Phillips G.B., Pinkernell B.H., and Jing T.Y. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler. Thromb. 14 5 (1994) 701-706
64. Yarnell J.W., Beswick A.D., Sweetnam P.M., and Riad-Fahmy D. Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study. Arterioscler. Thromb. 13 4 (1993) 517-520
65. Barrett-Connor E.L. Testosterone and risk factors for cardiovascular disease in men. Diabete Metab. 21 3 (1995) 156-161
66. Hurley B.F., Seals D.R., Hagberg J.M., Goldberg A.C., Ostrove S.M., Holloszy J.O., Wiest W.G., and Goldberg A.P. High-density-lipoprotein cholesterol in bodybuilders vs. powerlifters. Negative effects of androgen use. JAMA 252 4 (1984) 507-513
67. Thompson P.D., Cullinane E.M., Sady S.P., Chenevert C., Saritelli A.L., Sady M.A., and Herbert P.N. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 261 8 (1989) 1165-1168
68. Bhasin S., Storer T.W., Berman N., Callegari C., Clevenger B., Phillips J., Bunnell T., Tricker R., Shirazi A., and Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N. Engl. J. Med. 335 1 (1996) 1-7
69. Singh A.B., Hsia S., Alaupovic P., Sinha-Hikim I., Woodhouse L., Buchanan T.A., Shen R., Bross R., Berman N., and Bhasin S. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J. Clin. Endocrinol. Metab. 87 1 (2002) 136-143
70. Snyder P.J., Peachey H., Berlin J.A., Rader D., Usher D., Loh L., Hannoush P., Dlewati A., Holmes J.H., Santanna J., and Strom B.L. Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am. J. Med. 111 4 (2001) 255-260
71. Snyder P.J., Peachey H., Berlin J.A., Hannoush P., Haddad G., Dlewati A., Santanna J., Loh L., Lenrow D.A., Holmes J.H., Kapoor S.C., Atkinson L.E., and Strom B.L. Effects of testosterone replacement in hypogonadal men. J. Clin. Endocrinol. Metab. 85 8 (2000) 2670-2677
72. Dobs A.S., Bachorik P.S., Arver S., Meikle A.W., Sanders S.W., Caramelli K.E., and Mazer N.A. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J. Clin. Endocrinol. Metab. 86 3 (2001) 1026-1033
73. Moorjani S., Dupont A., Labrie F., Lupien P.J., Gagne C., Brun D., Giguere M., Belanger A., and Cusan L. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J. Clin. Endocrinol. Metab. 66 2 (1988) 314-322
74. Wallentin L., and Varenhorst E. Plasma lipoproteins during anti-androgen treatment by estrogens or orchidectomy in men with prostatic carcinoma. Horm. Metab. Res. 13 5 (1981) 293-297
75. Bulusu N.V., Lewis S.B., Das S., and Clayton Jr. W.E. Serum lipid changes after estrogen therapy in prostatic carcinoma. Urology 20 2 (1982) 147-150
76. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
77. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E., and Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 7 (1998) 605-613
78. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342 12 (2000) 836-843
79. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336 14 (1997) 973-979
80. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 15 (2000) 1767-1772
81. Pradhan A.D., Manson J.E., Rossouw J.E., Siscovick D.S., Mouton C.P., Rifai N., Wallace R.B., Jackson R.D., Pettinger M.B., and Ridker P.M. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the women's health initiative observational study. JAMA 288 8 (2002) 980-987
82. Lichtenstein M.J., Yarnell J.W., Elwood P.C., Beswick A.D., Sweetnam P.M., Marks V., Teale D., and Riad-Fahmy D. Sex hormones, insulin, lipids, and prevalent ischemic heart disease. Am. J. Epidemiol. 126 4 (1987) 647-657
83. Haffner S.M., Karhapaa P., Mykkanen L., and Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes 43 2 (1994) 212-219
84. Barrett-Connor E., and Khaw K.T. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78 3 (1988) 539-545
85. Simon D., Charles M.A., Nahoul K., Orssaud G., Kremski J., Hully V., Joubert E., Papoz L., and Eschwege E. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the telecom study. J. Clin. Endocrinol. Metab. 82 2 (1997) 682-685
86. Tsai E.C., Boyko E.J., Leonetti D.L., and Fujimoto W.Y. Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int. J. Obes. Relat. Metab. Disord. 24 4 (2000) 485-491
87. Tchernof A., Labrie F., Belanger A., and Despres J.P. Obesity and metabolic complications: contribution of dehydroepiandrosterone and other steroid hormones. J. Endocrinol. 150 Suppl. (1996) S155-S164
88. Hergenc G., Schulte H., Assmann G., and von Eckardstein A. Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. Atherosclerosis 145 1 (1999) 147-156
89. Simon D., Charles M.A., Lahlou N., Nahoul K., Oppert J.M., Gouault-Heilmann M., Lemort N., Thibult N., Joubert E., Balkau B., and Eschwege E. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care 24 12 (2001) 2149-2151
90. Maffei L., Murata Y., Rochira V., Tubert G., Aranda C., Vazquez M., Clyne C.D., Davis S., Simpson E.R., and Carani C. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J. Clin. Endocrinol. Metab. 89 1 (2004) 61-70
91. Ongphiphadhanakul B., Thamprajamchit S., Chanprasertyothin S., Chailurkit L., and Rajatanavin R. Effect of estrogen replacement on insulin sensitivity, serum lipid and bone resorption marker in hypogonadal males. Maturitas 42 1 (2002) 85-89
92. Dougherty R.H., Rohrer J.L., Hayden D., Rubin S.D., and Leder B.Z. Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels. Clin. Endocrinol. (Oxf) 62 2 (2005) 228-235
93. Leder B.Z., and Finkelstein J.S. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos. Int. 16 12 (2005) 1487-1494
94. Leder B.Z., Rohrer J.L., Rubin S.D., Gallo J., and Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J. Clin. Endocrinol. Metab. 89 3 (2004) 1174-1180